Cargando…

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis

OBJECTIVE: To evaluate the efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis (SpA). METHODS: ABILITY-2 is an ongoing phase III, multicenter study of adalimumab treatment. Eligible patients age ≥18 years fulfilled the Assessment of SpondyloArthritis i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mease, Philip, Sieper, Joachim, Van den Bosch, Filip, Rahman, Proton, Karunaratne, P Mahinda, Pangan, Aileen L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409087/ https://www.ncbi.nlm.nih.gov/pubmed/25545240 http://dx.doi.org/10.1002/art.39008

Ejemplares similares

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
por: Van den Bosch, Filip, et al.
Publicado: (2018)

Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain
por: Deodhar, Atul, et al.
Publicado: (2016)

Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
por: Sieper, Joachim, et al.
Publicado: (2019)

Peripheral spondyloarthritis: a neglected entity—state of the art
por: Carron, Philippe, et al.
Publicado: (2020)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
por: Poddubnyy, Denis, et al.
Publicado: (2018)

Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC
por: Weiß, Anja, et al.
Publicado: (2017)

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial
por: Ducourau, Emilie, et al.
Publicado: (2020)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study
por: Boel, Anne, et al.
Publicado: (2022)

Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
por: Torgutalp, Murat, et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
por: de Winter, Janneke J, et al.
Publicado: (2019)

Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis
por: Hoppe, Berthold, et al.
Publicado: (2021)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study
por: López-Medina, Clementina, et al.
Publicado: (2021)

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life
por: Imkamp, Maike, et al.
Publicado: (2018)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study
por: López-Medina, Clementina, et al.
Publicado: (2021)

Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Sepriano, Alexandre, et al.
Publicado: (2017)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
por: van der Heijde, D., et al.
Publicado: (2017)

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Regel, Andrea, et al.
Publicado: (2017)

Peripheral spondyloarthritis and psoriatic arthritis sine psoriase: are we dealing with semantics or clinically meaningful differences?
por: Ziade, Nelly, et al.
Publicado: (2022)

Comorbidity management in spondyloarthritis
por: López-Medina, Clementina, et al.
Publicado: (2020)

Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study
por: Fakih, Olivier, et al.
Publicado: (2023)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
por: Kiltz, Uta, et al.
Publicado: (2020)

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
por: Molto, Anna, et al.
Publicado: (2021)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
por: Deodhar, Atul, et al.
Publicado: (2019)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
por: Deodhar, Atul, et al.
Publicado: (2021)

Chronic but not inflammatory changes at the Achilles’ tendon differentiate patients with peripheral spondyloarthritis from other diagnoses – Results from a prospective clinical trial
por: Baraliakos, Xenofon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i1qb4om80rngpiu1rpdmt1805v